Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

UCB Pharma (VOGALENE And VOGALIB)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Two medicinal products. The portfolio comprises of development, manufacturing, marketing and sale of Vogalib(R) and Vogalene(R) medicines. They are approved for use in the symptomatic treatment of nausea and vomiting. The injectible is approved for the prevention of nausea and vomiting in patients under chemotherapy.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • France

UCB Pharma (VOGALENE And VOGALIB) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore UCB Pharma (VOGALENE And VOGALIB)‘s full profile, request access.

Request full access to PitchBook

UCB Pharma (VOGALENE And VOGALIB) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore UCB Pharma (VOGALENE And VOGALIB)‘s full profile, request access.

Request full access to PitchBook